Antibody Therapeutics for Life


PharmAbcine to Participate in BIO Digital Conference
  • Written by PharmAbcine
  • Written date 2020-05-28 09:12:23
  • Inquire 15781

PharmAbcine to Participate in BIO Digital Conference

Daejeon, Korea, May 26, 2020 - PharmAbcine Inc. (KOSDAQ: 208340) announced today that the company will be participating in BIO (Biotechnology Innovation Organization) Digital Conference over June 8-12.  The BIO International Convention is holding its annual 

event virtually this year amidst the COVID-19 global pandemic. The event brings together capital, scientific and development expertise 

needed to turn promising innovation into successful medicine.

During the digital gathering, PharmAbcine, a therapeutic antibody development company, will be holding virtual meetings with potential 

global partners to share information on its pre-clinical and clinical assets. Virtual meeting times are still available to those participating.

“By participating in BIO Digital, the company aims to introduce its front runner product, olinvacimab, an angiogenesis regulator, and the 

two new additions to its pipeline,” says Dr. Jin-San Yoo, CEO of PharmAbcine.  “The two new additions include 1) PMC-402, a TIE-2 

activating blood vessel stabilizer and 2) PMC-309, an anti-VISTA immune checkpoint inhibitor.”

About PharmAbcine Inc.

PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from 

oncology, immuno-oncology, ophthalmology, respiratory, to renal pathology.

PharmAbcine’s leading pipeline, olinvacimab, an anti-VEGFR2 neutralizing fully human IgG, is currently in a phase II study for Bevacizumab-nonresponding rGBM (recurrent glioblastoma multiforme) patients in both US and Australia. In collaboration with MERCK, 

olinvacimab plus pembrolizumab Phase Ib trials for mTNBC and rGBM are on-going.

PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine’s advanced 3G expression system accommodates high levels of antibody production with high reproducibility. With its highly advanced technology platforms, it provides high-quality 

antibody generation services. The high standards have allowed PharmAbcine to expand co-development opportunities with not only 

existing but also potential partners.

Additional information about PharmAbcine can be found on our website at


About the BIO International Convention:

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 

biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global 

biotech industry provides access to key partners, educational resources, and the insights for attendees to continue critical research and 


For more information visit


Yohan Jung


please visit the website at


Prev [ Re-announcement], AACR Annual Meeting 2020 Cancelled and Rescheduled for Later...
Next PharmAbcine signs a license agreement with Wincal Biopharm to expand indications...